drugset / Trial / NCT00557219

Fenoldopam and Ketanserin for Acute Kidney Failure Prevention After Cardiac Surgery

NCT00557219

Phase 3 Terminated 60 enrolled Medical University of Gdansk
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of the study is to compare the effect of fenoldopam and ketanserin on kidney function preservation in patients at high risk for renal failure after cardiac surgery. Acute, oliguric renal failure develops in up to 2% of patients undergoing cardiac surgery. Some of them require renal replacement therapy and despite that mortality in this group exceeds 30-60%. The investigators await that the use of fenoldopam and/or ketanserin may decrease the rate of severe renal failure.

Timeline

Start
2008-04
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenoldopam Small molecule 0.3 ug/kg Intravenous
Subject Ketanserin Small molecule 0.1 mg/kg Intravenous

Indications